Anti-Human CD47 (Clone B6H12) - DyLight 488

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Mouse

Immunogen

Purified Recombinant Human CD47 (> 98%)

Product Concentration

0.2 mg/ml

Formulation

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Handling

This DyLight^® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Country of Origin

USA

Shipping

Next Day 2-8°C

Excitation Laser

Blue Laser (493 nm)

RRID

AB_2829294

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone B6H12 recognizes an epitope on human CD47.

Antigen Distribution

CD47 is expressed on leukocytes, platelets, erythrocytes, epithelial cells, endothelial cells, fibroblasts, and is overexpressed in ovarian cancer, as well as many different tumor cells.

Background

CD47 is a 50 kD transmembrane protein receptor to the Ig superfamily that can manifest in four isoforms, differing only in the length of their cytoplasmic tail. CD47 is involved in various cellular processes including apoptosis, proliferation, adhesion, and migration, and plays a key role in immune and angiogenic responses. CD47 was first identified as a tumor antigen on human ovarian cancer and its expression has subsequently been found on multiple human tumor types such as acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), bladder cancer, and pediatric and adult brain tumors. CD47 interacts with membrane integrins, TSP-1, and SIRPα. The CD47/SIRPα interaction results in the inhibition of phagocytosis by macrophages thus, allowing cancer cells to multiply unchecked. Anti-CD47 antibody is a potential therapeutic target in a variety of cancers and for the treatment of pulmonary fibrosis. Anti-CD47 antibody treatment not only facilitates macrophage phagocytosis of cancer, but also promotes the activation of cancer-specific lymphocytes by acting as a beacon, flagging cancer cells which now display altered proteins to which the immune system can react.

Antigen Details

Protein

CD47

Ligand/Receptor

Non-covalently associated with ß3 integrins CD51/CD61, CD41/CD61. Thrombospondin is a ligand for CD47.

PubMed

CD47

NCBI Gene Bank ID

961

UniProt.org

Information on Uniprot.org

Research Area

Immunology

Technical Protocols